Mesoblast (NASDAQ:MESO) Stock Price Breaks Above Two Hundred Day Moving Average – Here’s What Happened

Mesoblast Limited (NASDAQ:MESO) passed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $15.45 and traded as high as $15.82. Mesoblast shares last traded at $15.67, with a volume of 696,476 shares traded.

Key Headlines Impacting Mesoblast

Here are the key news stories impacting Mesoblast this week:

• Positive Sentiment: Ryoncil revenue increased 44%. Mesoblast’s first-quarter fiscal 2027 update showed a 44% rise in net revenue, led by continued growth in Ryoncil sales. The result is strengthening the investment case that the company’s first approved therapy can become a meaningful commercial product. Mesoblast fiscal first-quarter activity report
• Positive Sentiment: Cash spending reportedly fell sharply. Coverage of the quarterly update highlighted a substantial reduction in cash burn, which could extend Mesoblast’s financial runway and reduce near-term financing risk. Mesoblast Ryoncil sales and cash burn update
• Positive Sentiment: Investors are reassessing Ryoncil’s growth potential. Analysts and market commentators suggested that accelerating Ryoncil sales could materially change the outlook for Mesoblast, helping explain the stock’s strong rally and increased trading attention. Ryoncil growth could change the case for Mesoblast stock
• Neutral Sentiment: Mesoblast was included in broader reports on Australian healthcare and founder-led companies, including screens identifying shares trading below estimated fair value. These lists may increase visibility but do not represent new company-specific fundamentals. Australian founder-led stocks trading below fair value
• Negative Sentiment: The recent rally raises the risk of profit-taking, while Mesoblast remains dependent on continued Ryoncil adoption and execution. Investors should also monitor whether revenue growth can translate into sustained profitability.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on MESO shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Mesoblast in a research report on Thursday, September 24th. Piper Sandler reissued an “overweight” rating and issued a $39.00 target price (up from $35.00) on shares of Mesoblast in a report on Thursday, August 27th. Finally, Weiss Ratings upgraded shares of Mesoblast from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 9th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $39.00.

Mesoblast Stock Down 3.3%

The firm has a 50 day moving average of $14.93 and a 200 day moving average of $15.43. The company has a debt-to-equity ratio of 0.19, a quick ratio of 2.09 and a current ratio of 2.43.

Mesoblast (NASDAQ:MESO) last announced its quarterly earnings data on Friday, July 31st. The company reported ($0.07) EPS for the quarter. The firm had revenue of $34.45 million for the quarter. As a group, research analysts predict that Mesoblast Limited will post -0.05 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of MESO. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Mesoblast in the third quarter worth approximately $39,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Mesoblast by 15.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,566 shares of the company’s stock valued at $142,000 after purchasing an additional 1,247 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Mesoblast by 14.1% during the second quarter. GAMMA Investing LLC now owns 7,413 shares of the company’s stock valued at $100,000 after buying an additional 916 shares during the last quarter. Bank of America Corp DE boosted its position in shares of Mesoblast by 608.4% during the first quarter. Bank of America Corp DE now owns 100,004 shares of the company’s stock valued at $1,538,000 after buying an additional 85,888 shares during the last quarter. Finally, Royal Bank of Canada grew its stake in shares of Mesoblast by 22.5% in the 1st quarter. Royal Bank of Canada now owns 26,266 shares of the company’s stock worth $404,000 after acquiring an additional 4,827 shares in the last quarter. Institutional investors and hedge funds own 1.43% of the company’s stock.

About Mesoblast

Mesoblast Limited is an Australia-based biotechnology company focused on developing and commercializing regenerative medicines made from specialized allogeneic mesenchymal lineage cells. The company’s platform is designed to produce “off-the-shelf” cellular therapies intended to address inflammation, tissue damage and impaired healing without requiring cells to be collected from each individual patient.

Mesoblast’s lead product, remestemcel-L, is marketed in the United States as RYONCIL.